vs
REV Group, Inc.（REVG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是REV Group, Inc.的1.2倍（$772.1M vs $664.4M），Revvity净利率更高（12.7% vs 4.3%，领先8.4%），REV Group, Inc.同比增速更快（11.1% vs 5.9%），Revvity自由现金流更多（$161.8M vs $53.7M），过去两年Revvity的营收复合增速更高（9.0% vs 6.5%）
REV Group是一家美国智能语音转文字服务提供商，总部位于旧金山和奥斯汀，成立于2010年，核心业务涵盖隐藏字幕制作、多语言字幕翻译及文字转录服务，曾获《PC Magazine》2018年编辑选择奖，2019年获评该杂志最佳转录服务提供商。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
REVG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$664.4M
营收增速更快
REVG
高出5.3%
5.9%
净利率更高
RVTY
高出8.4%
4.3%
自由现金流更多
RVTY
多$108.1M
$53.7M
两年增速更快
RVTY
近两年复合增速
6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $664.4M | $772.1M |
| 净利润 | $28.9M | $98.4M |
| 毛利率 | 15.4% | — |
| 营业利润率 | 7.1% | 14.5% |
| 净利率 | 4.3% | 12.7% |
| 营收同比 | 11.1% | 5.9% |
| 净利润同比 | -30.7% | 3.9% |
| 每股收益（稀释后） | $0.57 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收REVGRVTY
| Q4 25 | $664.4M | $772.1M | ||
| Q3 25 | $644.9M | $698.9M | ||
| Q2 25 | $629.1M | $720.3M | ||
| Q1 25 | $525.1M | $664.8M | ||
| Q4 24 | $597.9M | $729.4M | ||
| Q3 24 | $579.4M | $684.0M | ||
| Q2 24 | $616.9M | $691.7M | ||
| Q1 24 | $586.0M | $649.9M |
净利润REVGRVTY
| Q4 25 | $28.9M | $98.4M | ||
| Q3 25 | $29.1M | $46.7M | ||
| Q2 25 | $19.0M | $53.9M | ||
| Q1 25 | $18.2M | $42.2M | ||
| Q4 24 | $41.7M | $94.6M | ||
| Q3 24 | $18.0M | $94.4M | ||
| Q2 24 | $15.2M | $55.4M | ||
| Q1 24 | $182.7M | $26.0M |
毛利率REVGRVTY
| Q4 25 | 15.4% | — | ||
| Q3 25 | 15.8% | 53.6% | ||
| Q2 25 | 15.2% | 54.5% | ||
| Q1 25 | 13.3% | 56.5% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 13.5% | 56.3% | ||
| Q2 24 | 12.5% | 55.7% | ||
| Q1 24 | 10.7% | 54.6% |
营业利润率REVGRVTY
| Q4 25 | 7.1% | 14.5% | ||
| Q3 25 | 8.8% | 11.7% | ||
| Q2 25 | 7.9% | 12.6% | ||
| Q1 25 | 5.3% | 10.9% | ||
| Q4 24 | 5.8% | 16.3% | ||
| Q3 24 | 4.9% | 14.3% | ||
| Q2 24 | 3.7% | 12.4% | ||
| Q1 24 | -1.1% | 6.8% |
净利率REVGRVTY
| Q4 25 | 4.3% | 12.7% | ||
| Q3 25 | 4.5% | 6.7% | ||
| Q2 25 | 3.0% | 7.5% | ||
| Q1 25 | 3.5% | 6.4% | ||
| Q4 24 | 7.0% | 13.0% | ||
| Q3 24 | 3.1% | 13.8% | ||
| Q2 24 | 2.5% | 8.0% | ||
| Q1 24 | 31.2% | 4.0% |
每股收益（稀释后）REVGRVTY
| Q4 25 | $0.57 | $0.86 | ||
| Q3 25 | $0.59 | $0.40 | ||
| Q2 25 | $0.38 | $0.46 | ||
| Q1 25 | $0.35 | $0.35 | ||
| Q4 24 | $1.03 | $0.77 | ||
| Q3 24 | $0.35 | $0.77 | ||
| Q2 24 | $0.28 | $0.45 | ||
| Q1 24 | $3.06 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.7M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $416.3M | $7.3B |
| 总资产 | $1.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资REVGRVTY
| Q4 25 | $34.7M | $919.9M | ||
| Q3 25 | $36.0M | $931.4M | ||
| Q2 25 | $28.8M | $991.8M | ||
| Q1 25 | $31.6M | $1.1B | ||
| Q4 24 | $24.6M | $1.2B | ||
| Q3 24 | $50.5M | $1.2B | ||
| Q2 24 | $38.2M | $2.0B | ||
| Q1 24 | $87.9M | $1.7B |
股东权益REVGRVTY
| Q4 25 | $416.3M | $7.3B | ||
| Q3 25 | $387.3M | $7.4B | ||
| Q2 25 | $357.8M | $7.6B | ||
| Q1 25 | $428.8M | $7.6B | ||
| Q4 24 | $435.1M | $7.7B | ||
| Q3 24 | $394.6M | $7.9B | ||
| Q2 24 | $379.7M | $7.9B | ||
| Q1 24 | $496.1M | $7.8B |
总资产REVGRVTY
| Q4 25 | $1.2B | $12.2B | ||
| Q3 25 | $1.2B | $12.1B | ||
| Q2 25 | $1.2B | $12.4B | ||
| Q1 25 | $1.2B | $12.4B | ||
| Q4 24 | $1.2B | $12.4B | ||
| Q3 24 | $1.3B | $12.8B | ||
| Q2 24 | $1.3B | $13.4B | ||
| Q1 24 | $1.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $76.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $53.7M | $161.8M |
| 自由现金流率自由现金流/营收 | 8.1% | 21.0% |
| 资本支出强度资本支出/营收 | 3.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.66× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $190.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流REVGRVTY
| Q4 25 | $76.9M | $182.0M | ||
| Q3 25 | $60.3M | $138.5M | ||
| Q2 25 | $117.0M | $134.3M | ||
| Q1 25 | $-13.1M | $128.2M | ||
| Q4 24 | $68.6M | $174.2M | ||
| Q3 24 | $14.4M | $147.9M | ||
| Q2 24 | $40.1M | $158.6M | ||
| Q1 24 | $-69.7M | $147.6M |
自由现金流REVGRVTY
| Q4 25 | $53.7M | $161.8M | ||
| Q3 25 | $48.7M | $120.0M | ||
| Q2 25 | $105.6M | $115.5M | ||
| Q1 25 | $-18.0M | $112.2M | ||
| Q4 24 | $63.3M | $149.8M | ||
| Q3 24 | $8.5M | $125.6M | ||
| Q2 24 | $34.2M | $136.6M | ||
| Q1 24 | $-80.2M | $129.7M |
自由现金流率REVGRVTY
| Q4 25 | 8.1% | 21.0% | ||
| Q3 25 | 7.6% | 17.2% | ||
| Q2 25 | 16.8% | 16.0% | ||
| Q1 25 | -3.4% | 16.9% | ||
| Q4 24 | 10.6% | 20.5% | ||
| Q3 24 | 1.5% | 18.4% | ||
| Q2 24 | 5.5% | 19.7% | ||
| Q1 24 | -13.7% | 20.0% |
资本支出强度REVGRVTY
| Q4 25 | 3.5% | 2.6% | ||
| Q3 25 | 1.8% | 2.6% | ||
| Q2 25 | 1.8% | 2.6% | ||
| Q1 25 | 0.9% | 2.4% | ||
| Q4 24 | 0.9% | 3.4% | ||
| Q3 24 | 1.0% | 3.3% | ||
| Q2 24 | 1.0% | 3.2% | ||
| Q1 24 | 1.8% | 2.7% |
现金转化率REVGRVTY
| Q4 25 | 2.66× | 1.85× | ||
| Q3 25 | 2.07× | 2.97× | ||
| Q2 25 | 6.16× | 2.49× | ||
| Q1 25 | -0.72× | 3.03× | ||
| Q4 24 | 1.65× | 1.84× | ||
| Q3 24 | 0.80× | 1.57× | ||
| Q2 24 | 2.64× | 2.87× | ||
| Q1 24 | -0.38× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
REVG
| Specialty Vehicles | $507.4M | 76% |
| Recreational Vehicles | $157.2M | 24% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
